Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$2.05 - $6.1 $293 - $872
143 Added 19.07%
893 $3,000
Q2 2022

Aug 15, 2022

BUY
$0.78 - $1.9 $585 - $1,425
750 New
750 $1,000
Q4 2021

Feb 14, 2022

SELL
$2.35 - $5.58 $1,823 - $4,330
-776 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$2.25 - $3.03 $1,746 - $2,351
776 New
776 $2,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.